drugset / Trial / NCT00269399
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
Timeline
- Start
- 2005-12
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 400 mg | — |
| Comparator | Vancomycin | Other / unclassified | 125 mg | — |